Prescription drug · ANDA
Terazosin NDC 27241-290
Terazosin hydrochloride 5 mg/1 · Capsule · Oral · Ajanta Pharma USA Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 27241-290-01 | 27241029001 | 100 CAPSULE in 1 BOTTLE (27241-290-01)Marketed from May 12, 2025 | |
| 27241-290-10 | 27241029010 | 1000 CAPSULE in 1 BOTTLE (27241-290-10)Marketed from May 12, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Terazosin
- Generic name (nonproprietary)
- terazosin
- Active ingredients
- Terazosin hydrochloride — 5 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Ajanta Pharma USA Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 219482
- Marketing start
- Listing expires
- Other FDA classes
- Adrenergic alpha-Antagonists (Mechanism)
- Identifiers
- Product ID 27241-290_ec1b00c3-3d59-420a-a71c-e9bd9a8d02fdSPL ID ec1b00c3-3d59-420a-a71c-e9bd9a8d02fdSPL set ID bed99c2a-4266-4a2c-bb0f-7643fdafff78RxCUI 260376, 313215, 313217, 313219UNII D32S14F082UPC 0327241289019, 0327241291012, 0327241290015, 0327241288012
- Pharmacologic class
- alpha-Adrenergic Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N427241029001followed by a unit qualifier and the quantityPackage 27241-0290-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules. The long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin capsules are also indicated for the treatment of hypertension. Terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 219482
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Terazosin | Terazosin hydrochloride 10 mg/1 | CapsuleOral | Ajanta Pharma USA Inc. | 27241-291 |
| Terazosin | Terazosin hydrochloride 1 mg/1 | CapsuleOral | Ajanta Pharma USA Inc. | 27241-288 |
| Terazosin | Terazosin hydrochloride 2 mg/1 | CapsuleOral | Ajanta Pharma USA Inc. | 27241-289 |